Brief: Reata Pharmaceuticals Reports Q3 Adjusted Loss Of $1.47 Per Share

Reata Pharmaceuticals

08/11/2022 11:45

Nov 8 (Reuters) - Reata Pharmaceuticals Inc  RETA.O :
    * REATA PHARMACEUTICALS, INC. ANNOUNCES THIRD QUARTER 2022
FINANCIAL RESULTS AND PROVIDES AN UPDATE ON CLINICAL DEVELOPMENT
PROGRAMS
    * NDA FOR OMAVELOXOLONE FOR PATIENTS WITH FRIEDREICH'S
ATAXIA
UNDER REVIEW WITH PDUFA DATE OF FEBRUARY 28, 2023
    * REATA PHARMACEUTICALS - FDA DOES NOT PLAN TO HOLD AN
ADVISORY
COMMITTEE MEETING TO DISCUSS OMAVELOXOLONE NDA AND LATE CYCLE
MEETING HAS BEEN COMPLETED
    * PLAN TO SUBMIT AN MAA TO EUROPEAN MEDICINES AGENCY ("EMA")
FOR
OMAVELOXOLONE THIS YEAR
    * QTRLY ADJUSTED LOSS PER SHARE $1.47
    * REATA PHARMACEUTICALS - EXISTING CASH,CASH
EQUIVALENTS,MARKETABLE DEBT SECURITIES TO BE SUFFICIENT TO
ENABLE IT TO FUND OPERATIONS THROUGH END OF 2024
    * GAAP NET LOSS FOR Q3 OF 2022, WAS $79.0 MILLION, OR $2.16
PER
SHARE
    * Q3 EARNINGS PER SHARE VIEW $-2.18 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nBw3vMH3Pa 
Further company coverage:  RETA.O 
 ((Reuters.Briefs@thomsonreuters.com;))